$338.74 Million in Sales Expected for Envista Holdings Corporation (NASDAQ:NVST) This Quarter

Equities research analysts expect Envista Holdings Corporation (NASDAQ:NVST) to announce sales of $338.74 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Envista’s earnings. The highest sales estimate is $386.80 million and the lowest is $310.20 million. The firm is scheduled to announce its next earnings results on Tuesday, August 11th.

According to Zacks, analysts expect that Envista will report full year sales of $2.01 billion for the current fiscal year, with estimates ranging from $1.88 billion to $2.11 billion. For the next financial year, analysts forecast that the firm will post sales of $2.40 billion, with estimates ranging from $2.28 billion to $2.52 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Envista.

Envista (NASDAQ:NVST) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by ($0.07). The firm had revenue of $547.20 million for the quarter, compared to the consensus estimate of $569.07 million. The business’s revenue was down 17.1% on a year-over-year basis.

Several brokerages have commented on NVST. JPMorgan Chase & Co. raised their target price on shares of Envista from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Bank of America reiterated a “neutral” rating and issued a $18.00 target price (down from $19.50) on shares of Envista in a report on Wednesday, May 13th. Piper Sandler began coverage on shares of Envista in a report on Tuesday, June 16th. They issued a “neutral” rating and a $20.00 target price for the company. Credit Suisse Group decreased their target price on shares of Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, May 13th. Finally, Robert W. Baird decreased their price target on shares of Envista from $25.00 to $23.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $26.64.

Shares of NVST traded up $0.48 during mid-day trading on Friday, hitting $20.98. The company’s stock had a trading volume of 25,766 shares, compared to its average volume of 3,242,121. The firm has a 50-day moving average price of $19.78 and a 200 day moving average price of $23.05. Envista has a fifty-two week low of $10.08 and a fifty-two week high of $33.30.

A number of institutional investors and hedge funds have recently modified their holdings of NVST. Victory Capital Management Inc. bought a new position in Envista during the fourth quarter valued at approximately $815,000. New York State Common Retirement Fund bought a new position in Envista during the fourth quarter valued at approximately $891,000. Rhumbline Advisers bought a new position in Envista during the fourth quarter valued at approximately $3,754,000. State Street Corp bought a new position in Envista during the fourth quarter valued at approximately $44,878,000. Finally, Sei Investments Co. raised its position in Envista by 198.3% during the fourth quarter. Sei Investments Co. now owns 73,700 shares of the company’s stock valued at $2,194,000 after acquiring an additional 48,996 shares in the last quarter.

About Envista

Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.

Recommended Story: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Envista (NVST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Envista (NASDAQ:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.